MPM Oncology Impact Management »

Soleno Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Soleno Therapeutics (SLNO) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Soleno Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Soleno Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Soleno Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $10M 150k 67.60
2025-06-30 $4.2M 50k 83.78

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Soleno Therapeutics

FMR
Henderson Group
BlackRock
Vanguard Group
venBio Select Advisor
Wellington Management Company
Vivo Capital
State Street Corporation
Invesco
Caption Management
Adage Capital Partners GP
Commodore Capital
Braidwell
Millennium Management
Polar Capital Holdings

View all funds holding Soleno Therapeutics